{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T08:14:14Z","timestamp":1783498454534,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"A-med Zentiva Austria"},{"name":"Biogen Austria"},{"name":"Bristol Myers Squibb Austria"},{"name":"Genericon Pharma"},{"name":"Janssen-Cilag Austria"},{"name":"Juvise Austria"},{"name":"Merck Austria"},{"name":"Neuraxpharm Austria"},{"name":"Novartis Pharma Austria"},{"name":"Ratiopharm Austria"},{"name":"Roche Austria"},{"name":"Sanofi Austria"},{"DOI":"10.13039\/100032310","name":"Sandoz Austria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032310","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Stada Austria"},{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Efficacy and safety considerations in the treatment of multiple sclerosis (MS) change over a person's lifetime due to immunosenescence and the increasing prevalence of comorbidities with advancing age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives\/aims<\/jats:title>\n                    <jats:p>To evaluate the overall efficacy and safety of disease-modifying therapies in MS patients across different age groups using prospectively collected real-world data from a nationwide observational cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients from the Austrian MS Treatment Registry (AMSTR) who were receiving treatment with Alemtuzumab, Cladribine, Dimethyl fumarate, Fingolimod, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Ponesimod, Siponimod, and Teriflunomide for at least 12\u00a0months as of March 2025. Patients were categorized into two age groups:\u2009&lt;\u200950\u00a0years (n\u2009=\u20091,459) and\u2009\u2265\u200950\u00a0years (n\u2009=\u2009658).<\/jats:p>\n                    <jats:p>A generalized linear model (GLM) and Cox proportional hazards models were applied to assess treatment effects on annualized relapse rates (ARR) and changes in the Expanded Disability Status Scale (EDSS), including both progression and improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a mean treatment duration of 6.0\u00a0years (younger cohort) and 7.8\u00a0years (older cohort), the estimated mean ARR was 0.12 and 0.09, respectively (p\u2009&lt;\u20090.001). Cox regression analysis of time to first relapse yielded a hazard ratio (HR) of 1.34 (95% CI 1.12\u20131.60, p\u2009=\u20090.001), indicating a significantly higher relapse risk for the younger cohort.<\/jats:p>\n                    <jats:p>For sustained EDSS progression at 12 and 24\u00a0weeks, the corresponding HRs were 0.76 (95% CI 0.64\u20130.912, p\u2009=\u20090.003) and 0.70 (95% CI 0.58\u20130.85, p\u2009&lt;\u20090.001), respectively, demonstrating a higher risk of disability progression in the older cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicate that approximately one-third of treated MS patients in our registry are aged 50\u00a0years or older, underscoring the substantial presence of older patients in contemporary MS treatment cohorts. Furthermore, efficacy outcomes, including ARR and EDSS progression, differed significantly between younger and older age groups. These results suggest that both disease activity and chronological age are primary determinants of treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-026-13885-z","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:54:04Z","timestamp":1781272444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of age on efficacy and safety of disease modifying treatment\u2014insights from the Austrian Multiple Sclerosis Treatment Registry"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-781X","authenticated-orcid":false,"given":"Michael","family":"Guger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Heschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Di Pauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Gradl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kalcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Kvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Austrian MS Treatment Registry (AMSTR)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"13885_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106257","volume":"94","author":"MMA Baig","year":"2025","unstructured":"Baig MMA, Siddiqui FZ, Ashkar A, Naeem A, Ahmed S, Waqas SA (2025) Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: a systemic review and meta-analysis. Mult Scler Relat Disord 94:106257. https:\/\/doi.org\/10.1016\/j.msard.2025.106257","journal-title":"Mult Scler Relat Disord"},{"key":"13885_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104472","volume":"70","author":"R Berkovich","year":"2023","unstructured":"Berkovich R, Negroski D, Wynn D, Sellers D, Bzdek KG, Lublin AL, Rawlings AM, Quach C, Wells DP, Dumlao M, Bora A, Ranno AE, Luo KL, Chavin J, Hua LH, Becker D (2023) Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: a real-world retrospective multicenter analysis. Mult Scler Relat Disord 70:104472. https:\/\/doi.org\/10.1016\/j.msard.2022.104472","journal-title":"Mult Scler Relat Disord"},{"key":"13885_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106691","volume":"103","author":"G Bsteh","year":"2025","unstructured":"Bsteh G, Introcaso V, Gradl C, Traxler G, Barket R, F\u00f6ttinger F, Hammer HN, Krajnc N, Ponleitner M, Zrzavy T, Deisenhammer F, Pauli FD, Chan A, Berger T, Hoepner R, Hegen H (2025) Risk stratification for disease reactivation after therapy de-escalation\/discontinuation in relapsing multiple sclerosis by the VIAADISC score. Mult Scler Relat Disord 103:106691. https:\/\/doi.org\/10.1016\/j.msard.2025.106691","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"13885_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/13524585221122207","volume":"29","author":"A Chertcoff","year":"2023","unstructured":"Chertcoff A, Ng HS, Zhu F, Zhao Y, Tremlett H (2023) Polypharmacy and multiple sclerosis: a population-based study. Mult Scler (Houndmills, Basingstoke, England) 29(1):107\u2013118. https:\/\/doi.org\/10.1177\/13524585221122207","journal-title":"Mult Scler (Houndmills, Basingstoke, England)"},{"issue":"7","key":"13885_CR5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","volume":"22","author":"JR Corboy","year":"2023","unstructured":"Corboy JR, Fox RJ, Kister I, Cutter GR, Morgan CJ, Seale R, Engebretson E, Gustafson T, Miller AE, DISCOMS investigators (2023) Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial. Lancet Neurol 22(7):568\u2013577. https:\/\/doi.org\/10.1016\/S1474-4422(23)00154-0","journal-title":"Lancet Neurol"},{"key":"13885_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103490","volume":"58","author":"G Disanto","year":"2022","unstructured":"Disanto G, Moccia M, Sacco R, Spiezia AL, Carotenuto A, Brescia Morra V, Gobbi C, Zecca C (2022) Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Mult Scler Relat Disord 58:103490. https:\/\/doi.org\/10.1016\/j.msard.2022.103490","journal-title":"Mult Scler Relat Disord"},{"key":"13885_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103171","volume":"55","author":"S Epstein","year":"2021","unstructured":"Epstein S, Fong KT, De Jager PL, Levine L, Riley C, Wesley S, Vargas WS, Farber R (2021) Evaluation of ocrelizumab in older progressive multiple sclerosis patients. Mult Scler Relat Disord 55:103171. https:\/\/doi.org\/10.1016\/j.msard.2021.103171","journal-title":"Mult Scler Relat Disord"},{"key":"13885_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.msard.2017.01.009","volume":"12","author":"J Fagius","year":"2017","unstructured":"Fagius J, Feresiadou A, Larsson E-M, Burman J (2017) Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. Mult Scler Relat Disord 12:82\u201387. https:\/\/doi.org\/10.1016\/j.msard.2017.01.009","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"13885_CR9","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, van der Walt A, Dwyer C, Buzzard K, Spies J, Parratt J, van Pesch V, Willekens B, Perrotta G, Bartholom\u00e9 E, Grand\u2019Maison F, Jacques F, Giacomini P, Vosoughi R, Girard J-M, de Seze J, Lebrun Frenay C, Ruet A, Laplaud D-A, Reifschneider G, Wagner B, Rauer S, Pul R, Seipelt M, Berthele A, Klotz L, Kallmann B-A, Paul F, Achiron A, Lus G, Centonze D, Patti F, Grimaldi L, Hupperts R, Frequin S, Fermont J, Madueno SE, Alonso Torres AM, Costa-Frossard Fran\u00e7a L, Meca-Lallana JE, Ruiz LB, Pearson O, Rog D, Evangelou N, Ismail A, Lathi E, Fox E, Leist T, Sloane J, Wu G, Khatri B, Steingo B, Thrower B, Gudesblatt M, Calkwood J, Bandari D, Scagnelli C, Laganke C, Robertson D, Kipp L, Belkin M, Cohan S, Goldstick L, Courtney A, Vargas W, Sylvester A, Srinivasan J, Kannan M, Picone M, English J, Napoli S, Balabanov R, Zaydan I, Nicholas J, Kaplan J, Lublin F, Riser E, Miller T, Alvarez E, Wray S, Gross J, Pawate S, Hersh C, McCarthy L, Crayton H, Graves J (2022) Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol 21(7):608\u2013619. https:\/\/doi.org\/10.1016\/S1474-4422(22)00143-0","journal-title":"Lancet Neurol"},{"issue":"19","key":"13885_CR10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS, HERCULES Trial Group (2025) Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med 392(19):1883\u20131892. https:\/\/doi.org\/10.1056\/NEJMoa2415988","journal-title":"N Engl J Med"},{"key":"13885_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763433","volume":"12","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP (2021) Integrated lymphopenia analysis in younger and older patients with multiple sclerosis treated with cladribine tablets. Front Immunol 12:763433. https:\/\/doi.org\/10.3389\/fimmu.2021.763433","journal-title":"Front Immunol"},{"issue":"6","key":"13885_CR12","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s00415-024-12286-4","volume":"271","author":"Y Goereci","year":"2024","unstructured":"Goereci Y, Ellenberger D, Rommer P, Dunkl V, Golla H, Zettl U, Stahmann A, Warnke C (2024) Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry. J Neurol 271(6):3409\u20133416. https:\/\/doi.org\/10.1007\/s00415-024-12286-4","journal-title":"J Neurol"},{"issue":"2","key":"13885_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/ane.12864","volume":"137","author":"M Guger","year":"2018","unstructured":"Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T (2018) Real-life clinical use of natalizumab and fingolimod in Austria. Acta Neurol Scand 137(2):181\u2013187. https:\/\/doi.org\/10.1111\/ane.12864","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"13885_CR14","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s00415-020-09811-6","volume":"267","author":"M Guger","year":"2020","unstructured":"Guger M, Enzinger C, Leutmezer F, Kraus J, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR) (2020) Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method. J Neurol 267(7):2090\u20132100. https:\/\/doi.org\/10.1007\/s00415-020-09811-6","journal-title":"J Neurol"},{"issue":"7","key":"13885_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS (2016) Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73(7):790\u2013794. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0826","journal-title":"JAMA Neurol"},{"key":"13885_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104766","volume":"75","author":"LH Hua","year":"2023","unstructured":"Hua LH, Bar-Or A, Cohan SL, Lublin FD, Coyle PK, Cree BA, Meng X, Su W, Cox GM, Fox RJ (2023) Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: post hoc analyses from the EXPAND study. Mult Scler Relat Disord 75:104766. https:\/\/doi.org\/10.1016\/j.msard.2023.104766","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"13885_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1159\/000542632","volume":"59","author":"S Iaquinto","year":"2025","unstructured":"Iaquinto S, Chan A, Manjaly Z-M, Staniki\u0107 M, Ineichen BV, Kuhle J, Haag C, M\u00fcller J, Yaldizli \u00d6, Kamm CP, Calabrese P, Zecca C, Magnusson T, Ammann S, Kesselring J, Baum C, Kaminski M, Puhan MA, von Wyl V (2025) Rising prevalence of multiple sclerosis in Switzerland: results from the Swiss multiple sclerosis registry. Neuroepidemiology 59(6):623\u2013632. https:\/\/doi.org\/10.1159\/000542632","journal-title":"Neuroepidemiology"},{"issue":"5","key":"13885_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","volume":"81","author":"G Jouvenot","year":"2024","unstructured":"Jouvenot G, Courbon G, Lefort M, Rollot F, Casey R, Le Page E, Michel L, Edan G, de Seze J, Kremer L, Bigaut K, Vukusic S, Mathey G, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al-Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanch\u00e9 J-P, Doghri I, Moulin S, Ben-Nasr H, Labeyrie C, Hankiewicz K, Neau J-P, Pottier C, Nifle C, Collongues N, Kerbrat A, Cotton F, Douek P, Guillememin F, Pachot A, Olaiz J, Rigaud-Bully C, Marignier R, Debouverie D, Lubetzki C, Cohen M, Fromont A, Wiertlewsky S, Audoin B, Giannesini C, Gout O, Montcuquet A, Bakchine S, Maurousset A, Maubeuge N, OFSEP Investigators (2024) High-efficacy therapy discontinuation vs continuation in patients 50 years and older with nonactive MS. JAMA Neurol 81(5):490\u2013498. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0395","journal-title":"JAMA Neurol"},{"key":"13885_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2022.900028","volume":"3","author":"K-A Lee","year":"2022","unstructured":"Lee K-A, Flores RR, Jang IH, Saathoff A, Robbins PD (2022) Immune senescence, immunosenescence and aging. Front Aging 3:900028. https:\/\/doi.org\/10.3389\/fragi.2022.900028","journal-title":"Front Aging"},{"key":"13885_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1197212","volume":"14","author":"G Macaron","year":"2023","unstructured":"Macaron G, Larochelle C, Arbour N, Galmard M, Girard JM, Prat A, Duquette P (2023) Impact of aging on treatment considerations for multiple sclerosis patients. Front Neurol 14:1197212. https:\/\/doi.org\/10.3389\/fneur.2023.1197212","journal-title":"Front Neurol"},{"issue":"4","key":"13885_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40261-022-01129-7","volume":"42","author":"CB Malpas","year":"2022","unstructured":"Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Kappos L, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T, the MSBase Study Group (2022) Multiple sclerosis relapses following cessation of fingolimod. Clin Drug Investig 42(4):355\u2013364. https:\/\/doi.org\/10.1007\/s40261-022-01129-7","journal-title":"Clin Drug Investig"},{"issue":"1","key":"13885_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12325-024-03047-w","volume":"42","author":"Y Mao-Draayer","year":"2025","unstructured":"Mao-Draayer Y, Bar-Or A, Balashov K, Foley J, Smoot K, Longbrake EE, Robertson D, Mendoza JP, Lewin JB, Everage N, Bo\u017ein I, Lyons J, Mokliatchouk O, Bame E, Giuliani F (2025) Real-world safety and effectiveness of dimethyl fumarate in patients with MS: results from the ESTEEM Phase 4 and PROCLAIM Phase 3 studies with a focus on older patients. Adv Ther 42(1):395\u2013412. https:\/\/doi.org\/10.1007\/s12325-024-03047-w","journal-title":"Adv Ther"},{"issue":"2","key":"13885_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/ene.13536","volume":"25","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F (2018) ECTRIMS\/EAN guideline on the pharmacological treatment of people with Multiple Sclerosis. Eur J Neurol 25(2):215\u2013237. https:\/\/doi.org\/10.1111\/ene.13536","journal-title":"Eur J Neurol"},{"issue":"22","key":"13885_CR24","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","volume":"76","author":"PW O\u2019Connor","year":"2011","unstructured":"O\u2019Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with Multiple Sclerosis. Neurology 76(22):1858\u20131865. https:\/\/doi.org\/10.1212\/WNL.0b013e31821e7c8a","journal-title":"Neurology"},{"key":"13885_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241284372","volume":"17","author":"C Oreja-Guevara","year":"2024","unstructured":"Oreja-Guevara C, Mart\u00ednez-Y\u00e9lamos S, Eichau S, Llaneza M\u00c1, Mart\u00edn-Mart\u00ednez J, Pe\u00f1a-Mart\u00ednez J, Meca-Lallana V, Alonso-Torres AM, Moral-Torres E, R\u00edo J, Calles C, Ares-Luque A, Rami\u00f3-Torrent\u00e0 L, Marzo-Sola ME, Prieto JM, Mart\u00ednez-Gin\u00e9s ML, Arroyo R, Otano-Mart\u00ednez M\u00c1, Brieva-Ruiz L, G\u00f3mez-Guti\u00e9rrez M, Rodr\u00edguez-Antig\u00fcedad A, Gal\u00e1n S\u00e1nchez-Seco V, Costa-Frossard L, Hern\u00e1ndez-P\u00e9rez M\u00c1, Landete-Pascual L, Gonz\u00e1lez-Platas M, Meca-Lallana JE (2024) Beyond lines of treatment: Embracing early high-efficacy disease-modifying treatments for Multiple Sclerosis management. Ther Adv Neurol Disord 17:17562864241284372. https:\/\/doi.org\/10.1177\/17562864241284372","journal-title":"Ther Adv Neurol Disord"},{"key":"13885_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123052","volume":"461","author":"MA Piedrabuena","year":"2024","unstructured":"Piedrabuena MA, Correale J, Fiol M, Marrodan M, Rojas JI, Alonso M, Pappolla A, Miguez J, Patrucco L, Cristiano E, Vrech C, Cohen L, Alonso R, Silva B, Luetic G, Deri N, Burgos M, Liwacki S, Piedrabuena R, Tkachuk V, Barboza A, Martinez A, Balbuena ME, Pinheiro AA, Nofal P, Lopez PA, Tavolini D, Leguizamon F, Hryb JP, Tizio S, Recchia L, Reich E, Contentti EC, Marcilla MP, Pagani F, Cabrera LM, Curbelo MC, Mainella C, Liguori NF, Coppola M, Pettinicchi JP, Carra A, Jose G, Nadur D, Bestoso S, Pestchanker C, Vazquez GD, Martinez CM, Ysrraelit MC (2024) Selection of disease modifying therapies in Multiple Sclerosis based on patient\u2019s age and disease activity: Data from a nationwide registry. J Neurol Sci 461:123052. https:\/\/doi.org\/10.1016\/j.jns.2024.123052","journal-title":"J Neurol Sci"},{"issue":"5","key":"13885_CR27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209135","volume":"102","author":"A Salter","year":"2024","unstructured":"Salter A, Lancia S, Kowalec K, Fitzgerald KC, Marrie RA (2024) Investigating the prevalence of comorbidity in Multiple Sclerosis clinical trial populations. Neurology 102(5):e209135. https:\/\/doi.org\/10.1212\/WNL.0000000000209135","journal-title":"Neurology"},{"issue":"10","key":"13885_CR28","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1007\/s00415-024-12584-x","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Hartung H-P, Mycko MP, Selmaj I, Cross AH (2024) MS treatment de-escalation: Review and commentary. J Neurol 271(10):6426\u20136438. https:\/\/doi.org\/10.1007\/s00415-024-12584-x","journal-title":"J Neurol"},{"key":"13885_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105830","volume":"90","author":"B Silva","year":"2024","unstructured":"Silva B, Casales F, Donoso CB, Varela L, Heriz A, Gonzalez C, M\u00edguez J, Alonso R (2024) Safety of high efficacy therapies in older people with Multiple Sclerosis: a real-world evidence study. Mult Scler Relat Disord 90:105830. https:\/\/doi.org\/10.1016\/j.msard.2024.105830","journal-title":"Mult Scler Relat Disord"},{"key":"13885_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799138","volume":"12","author":"BL Vollmer","year":"2022","unstructured":"Vollmer BL, Wolf AB, Sillau S, Corboy JR, Alvarez E (2022) Evolution of disease modifying therapy benefits and risks: An argument for de-escalation as a treatment paradigm for patients with Multiple Sclerosis. Front Neurol 12:799138. https:\/\/doi.org\/10.3389\/fneur.2021.799138","journal-title":"Front Neurol"},{"issue":"10","key":"13885_CR31","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG, US Multiple Sclerosis Prevalence Workgroup (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92(10):e1029\u2013e1040. https:\/\/doi.org\/10.1212\/WNL.0000000000007035","journal-title":"Neurology"},{"key":"13885_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00577","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2017.00577","journal-title":"Front Neurol"},{"key":"13885_CR33","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211039648","volume":"14","author":"H Wiendl","year":"2021","unstructured":"Wiendl H, Gold R, Berger T, Derfuss T, Linker R, M\u00e4urer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung H-P, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, L\u00fcnemann JD, Lutterotti A, Meuth SG, Meyding-Lamad\u00e9 U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, Multiple Sclerosis Therapy Consensus Group (MSTCG) (2021) Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for Multiple Sclerosis (white paper). Ther Adv Neurol Disord 14:17562864211039648. https:\/\/doi.org\/10.1177\/17562864211039648","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"13885_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00415-023-12041-1","volume":"271","author":"A Zinganell","year":"2024","unstructured":"Zinganell A, G\u00f6bel G, Berek K, Hofer B, Asenbaum-Nan S, Barang M, B\u00f6ck K, Bsteh C, Bsteh G, Eger S, Eggers C, Fertl E, Joldic D, Khalil M, Langenscheidt D, Komposch M, Kornek B, Kraus J, Krendl R, Rauschka H, Sellner J, Auer M, Hegen H, Pauli FD, Deisenhammer F (2024) Multiple sclerosis in the elderly: a retrospective cohort study. J Neurol 271(2):674\u2013687. https:\/\/doi.org\/10.1007\/s00415-023-12041-1","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13885-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:21:36Z","timestamp":1783495296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13885-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["13885"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13885-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Guger received support and honoraria for research, consultation, lectures and education from\u00a0Alexion, Almirall, Bayer, Biogen, Celgene, Genzyme, Horizon, Janssen, MedDay, Merck, Neuraxpharm, Novartis, Roche, Sandoz, Sanofi Aventis and TEVA ratiopharm. Christian Enzinger received funding for travel and speaker honoraria from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Shire, and Teva Pharmaceutical Industries Ltd.\/sanofi-aventis, research support from Biogen, Merck, and Teva Pharmaceutical Industries Ltd.\/sanofi-aventis and serving on scientific advisory boards for Bayer, Biogen, Merck, Novartis, Rochen and Teva Pharmaceutical Industries Ltd.\/sanofi- Aventis. Bettina Heschl received funding for travel and speaker honoraria from Bayer, Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi and Teva. Franziska Di Pauli has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Amgen, Bayer, Biogen, Celgene, Merck, Neuraxpharm, Novartis, Sandoz, Sanofi-Genzyme, Roche and Teva. Christiane Gradl has participated in meetings sponsored by or received honoraria (lectures, advisory boards, consultations) and\/or travel funding from Alexion, Almirall, Biogen, Bristol-Myers-Squibb, D-Pharma, Horizon, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda Pharmaceutical and Teva-ratiopharm. Stefan Kalcher declares that there is no conflict of interest. Erich Kvas declares that there is no conflict of interest. Thomas Berger has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Bayer, Biogen, Biologix, Bionorica, Bristol-Myers-Squibb, Eisai, GW Pharma, Horizon, Janssen-Cilag, MedDay, Merck, Neuraxpharm, Novartis, Octapharma, Roche, Sandoz, Sanofi, TG Pharmaceuticals, TEVA-ratiopharm and UCB. His institution has received financial support in the last 12\u00a0months by unrestricted research grants (Biogen, Bayer, Bristol-Myers-Squibb, Merck, Novartis, Sanofi, and TEVA ratiopharm) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Bristol-Myers-Squibb, Merck, Novartis, Octapharma, Roche, Sanofi, and TEVA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The AMSTR complies with Austrian bioethics laws and was approved by the Ethics Committee of the Medical University of Vienna (EC number 2096\/2013).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"392"}}